Your session is about to expire
← Back to Search
Positron Emission Tomography/Computed Tomography for Prostate Cancer
Study Summary
This trial will test if a new imaging method can better detect prostate cancer recurrence than current methods, and if so, if it can help guide treatment decisions.
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current enrolment rate for this research study?
"Affirmative. Data from clinicaltrials.gov demonstrates that this trial, which was initially advertised on March 19th 2021, is currently searching for participants. The team needs to recruit 50 people from a single medical centre."
Are there any vacancies available for participants in this clinical research study?
"According to clinicaltrials.gov, the study is currently enlisting participants. The trial was first published on March 19th 2021 and the most recent update occurred on February 3rd 2022."
Is the FDA compliant with Positron Emission Tomography/Computed Tomography?
"Positron Emission Tomography/Computed Tomography received a safety score of 2 on the scale from 1 to 3. This is because it has completed Phase 2 trials, wherein some proof of its security was established yet there remains no evidence for its efficacy."
Share this study with friends
Copy Link
Messenger